astra zeneca master thesis

• Gå till innehåll
• Gå till navigation

Early Talent Careers

Kickstart your career together with us and create connections that will last a lifetime.

Elementary & High School

Read more about Mälardalens Technical High school and the ”Summer Science School”.

For students, we offer thesis work, holiday work and internships.

Our Global Graduate Programmes offer a great opportunity for individual learning and growth. Join one of our Global Graduate Programmes and gain the tools and experience to fulfil your future career goals.

Other Early Talent opportunities

Besides our Global Graduate programmes, we offer other opportunities for graduates. Take a look!

At AstraZeneca Sweden, we offer multiple opportunities for students and graduates.

Working on real projects with high levels of responsibility, you’ll have the freedom and support to grow your skillset in an exciting new environment. At AstraZeneca, we truly value the unique knowledge and ideas from early talent. In our graduate programmes, you will be able to help us increase the access to healthcare.

We’re looking for people who want to make an impact. Those willing to take initiatives and enjoy new challenges. Our teams at AstraZeneca are highly collaborative and passionate about what they do. Being a part of our organisation gives you the opportunity to expand your skills while having a supportive network around you.

Join an AstraZeneca Early Talent Programme and help us deliver life-saving medicines to millions of patients around the world. All whilst applying your knowledge and expanding your skills!

Start your career journey at AstraZeneca

Explore the opportunities at a global pharmaceutical company - ranging from Thesis Work to Internships and Campus Ambassador Programmes!

Thesis work

At AstraZeneca, we invite bachelor's and master's students to a new journey in their academic and professional career. This is an opportunity to build long lasting relationships, learn and grow, and explore your strengths in a new environment. We've got a wide range of exciting thesis projects happening every spring and fall across our business areas. So, why not join us and take your career to the next level? It all starts right here at AstraZeneca.  Application period for spring thesis works opens in August.

Application period for fall thesis works opens in January.

Our thesis works are posted on our career pages. If you have a great idea for a thesis project, you can register your interest and send in your idea through our “declaration of interest ad”. The ad normally opens approximately 1-2 months before the application period.

Holiday work 

AstraZeneca offers summer holiday work in partnership with KellyOCG. Don’t miss the opportunity to explore your interests, gaining work experience, and build a professional network.

Application period: End of January – March. Apply here!

Internship & Industrial Placement

At AstraZeneca we believe in having a multigenerational workforce and we offer different types of internships and industrial placements. Take the chance to be part of making a difference, making connections, and make a positive impact on your professional development. We advertise these opportunities continuously throughout the year.

Campus Ambassador Programme:

Being a student ambassador for AstraZeneca means being our external voice at your local university and working actively to increase the knowledge about AstraZeneca on campus. Over the course of a year, you will be part of a wider network of Campus Ambassadors across universities in Sweden. In the program, you will receive a mentor from AstraZeneca who you will have regular meetings with, providing you with insight about working at one of the world's leading pharmaceutical companies. The program is a great opportunity to gain hands-on experience in communication, marketing, and event coordination.

Elevate your university journey by becoming an AstraZeneca Student Ambassador!  Application period: October – November

Elementary & High School Students

Are you a high school student or about to apply?

Explore the opportunities for Elementary and High School students below.

Applying to high school:

Mälardalens Technical High School is a unique collaboration between AstraZeneca, Scania and Telge. The students are offered internships, holiday jobs and employment for at least six months at one of the companies in the collaboration. Find more information about Mälardalens Technical High School here.

For Elementary & High School students:

We give students an insight into our business to help you in your future career choice. Every summer we hold a research school, which is an effort to increase interest in science and technology among young people. It is aimed for young people in 8 th – 9 th grade and year one in high school. The research school is available in both Stockholm and Gothenburg.

Find more information about summer science school here .

Other Early Talent Opportunities

Visit our careers page for more information

LUMINI Graduate Programme:

Are you a newly graduated engineer who wants to explore the opportunities within a global biopharmaceutical company? Our LUMINI Graduate Programme could be the perfect start to your career. You’ll gain invaluable insights, experiences, and opportunities across our diverse, dynamic, and international organization. In this local graduate programme, you will be working at Sweden Operations, the “heart” of AstraZeneca’s production in Södertälje, which is our largest manufacturing site. The production facilities here have an influential role in the development and delivery of products all over the world. This is your opportunity to work on real projects, supported by some of the best people the industry has to offer. The programme lasts two years, consisting of three rotations in Södertälje and includes permanent employment. Your rotations will be decided based on your own development plan, combined with the organization's strategic business needs. Application period opens in December, find the open ad on our careers page.

Careers at AstraZeneca:

Besides our Early Talent Programmes, AstraZeneca are constantly looking for new talent. Please visit our careers page which is updated with our current job opportunities.

SE-14997-10-24

Read more about our career opportunities

Visit our career page

Du lämnar nu AstraZeneca.se

Du har klickat på en länk som tar dig till en annan webbplats. Vissa länkar tar dig till AstraZeneca.com. Du omdirigeras då till AstraZenecas globala hemsida avsedd för en global målgrupp, och lämnar därmed AstraZenecas svenska hemsida.

AstraZeneca tar inget ansvar för innehållet på externa webbplatser.

Klicka på ‘avbryt’ för att gå tillbaka till AstraZeneca.se eller välj ‘fortsätt’ för att gå vidare.

Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• 08 December 2020

Oxford COVID-vaccine paper highlights lingering unknowns about results

• Heidi Ledford

You can also search for this author in PubMed   Google Scholar

The first formally published results from a large clinical trial of a COVID-19 vaccine — which scientists hope could be among the cheapest and easiest to distribute around the world — suggest that the vaccine is safe and effective. But the data also highlight a number of lingering unknowns, including questions about the most effective dosing regimen and how well it works in older adults.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 51 print issues and online access

185,98 € per year

only 3,65 € per issue

Rent or buy this article

Prices vary by article type

Prices may be subject to local taxes which are calculated during checkout

Nature 588 , 378-379 (2020)

doi: https://doi.org/10.1038/d41586-020-03504-w

Voysey, M. et al. Lancet https://doi.org/10.1016/S0140-6736(20)32661-1 (2020).

Article   Google Scholar  

Ramasamy, M. N. et al. Lancet https://doi.org/10.1016/S0140-6736(20)32466-1 (2020).

Download references

Reprints and permissions

Related Articles

Why emergency COVID-vaccine approvals pose a dilemma for scientists

Trials that infected people with common colds can inform today’s COVID-19 challenge trials

Correspondence 21 MAY 24

A global pandemic treaty is in sight: don’t scupper it

Editorial 21 MAY 24

US halts funding to controversial virus-hunting group: what researchers think

News 16 MAY 24

Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines

Article 15 MAY 24

Vaccine-enhancing plant extract could be mass produced in yeast

News & Views 08 MAY 24

Assistant, Associate or Full Professor

The McLaughlin Research Institute and Touro University – Montana campus invite applications for open rank faculty positions.

McLaughlin Research Institute

Postdoctoral Associate- Neuroscience

Houston, Texas (US)

Baylor College of Medicine (BCM)

Call for applications- junior and senior scientists

The BORDEAUX INSTITUTE OF ONCOLOGY (BRIC U1312, https://www.bricbordeaux.com/) is seeking to recruit new junior and senior researchers

Bordeaux (Ville), Gironde (FR)

INSERM - U1312 BRIC

Postdoctoral Scholar - Organic Synthesis

Memphis, Tennessee

The University of Tennessee Health Science Center (UTHSC)

Postdoctoral Scholar - Chemical Biology

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Navigation Menu

Search code, repositories, users, issues, pull requests..., provide feedback.

We read every piece of feedback, and take your input very seriously.

Saved searches

Use saved searches to filter your results more quickly.

To see all available qualifiers, see our documentation .

• Notifications You must be signed in to change notification settings

This repository contains the report and R-package from my master thesis in mathematical statistics. This master thesis was done in collaboration with the pharmaceutical company AstraZeneca.

Abbe94/Multidimensional-Decision-making-in-clinical-trials

Folders and files.

JHM Professional Development and Career Office Awareness. Preparation. Development.

Johns hopkins-astrazeneca scholars program, about the program.

The Johns Hopkins-AstraZeneca Scholars Program (formerly known as Johns Hopkins-MedImmune Scholars Program) is a first-of-its-kind Ph.D. training program jointly implemented by the Johns Hopkins University’s Center for Innovation in Graduate Biomedical Education and AstraZeneca, the global research-based biopharmaceutical company. Students in this program will be mentored by a pair of co-supervisors, one at Johns Hopkins and the other at AstraZeneca. In addition to the standard Johns Hopkins course curriculum and Ph.D. thesis project, students will be introduced to the process and challenges of drug discovery and development through coursework in translational research as well as lab work conducted at AstraZeneca under the direction of AstraZeneca co-supervisors. This unique approach to training will offer graduate students hands-on experience in the biomedical field and prepare them for careers in the biopharma industry, while still obtaining a traditional Ph.D. from a world-class university.

Current Scholars

Click on each name for more information.

Program Eligibility

Graduate students enrolled in Ph.D.-granting programs (entering 2016 or later) at any of the schools of the Johns Hopkins University are eligible to apply for the program as long as co-supervisors can be identified with an agreeable joint Ph.D. thesis project plan.

Application Process

In order to minimize the upfront burden of paperwork, the application process for the Johns Hopkins-AstraZeneca Scholars Program is intentionally kept informal at the early phase. The key question at this phase is whether joint Ph.D. thesis plans can be developed by students and co-supervisors. Dr. Takashi Tsukamoto, Program Director, will facilitate this process by working closely with potential students and co-supervisors. Once agreeable plans are established, the process enters more formal steps including in-depth review of the applications by the Johns Hopkins AstraZeneca Joint Committee for final decision.

Course Requirements

In addition to courses required by the home graduate program, Johns Hopkins-AstraZeneca Scholars must complete the three courses listed below on translational research. These courses are offered by Johns Hopkins Drug Discovery and are designed to cover various topics on drug discovery and development to complement the basic science courses offered by the home graduate programs.

• Introduction to Drug Discovery Research (ME:200.704)
• Drug Discovery Case Studies (ME:200.707)
• Pharmaceutical Enterprise (ME:200.708)

If you are interested but undecided on whether to apply for the Johns Hopkins-AstraZeneca Scholars Program, it may be beneficial to start taking these courses as electives in your graduate program to avoid excessive course load in the later years.

Students With Disabilities

The Johns Hopkins-AstraZeneca Scholars Program encourages students with disabilities to apply for the program. Johns Hopkins University is committed to providing reasonable and appropriate accommodations to students with disabilities. Students with documented disabilities should contact the coordinator listed on the Disability Accommodations page.

Learning More About The Program

If you are a graduate student and interested in becoming a Johns Hopkins-AstraZeneca Scholar, the first step is to contact Dr. Tsukamoto, who will guide you through the process of exploring the feasibility of being selected for the program. If you are a Johns Hopkins principal investigator affiliated with a Ph.D.-granting program and are interested in learning more about potential opportunities to work with AstraZeneca investigators through this program for future graduate students, Dr. Tsukamoto can serve as a point person to facilitate the communication with the AstraZeneca counterpart.

Program Director

Takashi Tsukamoto Ph.D. Associate Professor of Neurology Johns Hopkins Drug Discovery Johns Hopkins University 855 N Wolfe Street, Rangos 231 Baltimore, MD 21205 [email protected]

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Ann Med Surg (Lond)
• v.65; 2021 May

Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries

Dear Editor,

The safety and efficacy of coronavirus disease 2019 (COVID-19) vaccine in older adults have been eagerly anticipated owing to the 23-fold greater risk of death due to COVID-19 in adults over 65 years of age [ 1 ]. Maheshi Ramasamy and colleagues [ 2 ] have recently presented the safety and immunogenicity of AZD1222 (previously ChAdOx1 nCoV-19), the COVID-19 vaccine candidate of AstraZeneca/Oxford, including adults aged 70 years and more. The vaccine seems to be better tolerated in older adults, exhibiting similar immunogenicity, irrespective of age, following the booster dose [ 2 ]. The inclusion of older adult populations in the vaccine trials help to understand how health status and frailty can influence vaccine efficacy, safety, immunogenicity, and reactogenicity in older adults [ 3 ]. The plan of AstraZeneca to expand their manufacturing capacity to 3 billion doses in 2021 is a major step in attaining 100% global vaccination coverage [ 4 ]. This correspondence aims to analyze the major COVID-19 vaccines developed by AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna, in terms of safety, efficacy, cost, storage, and transportation.

1. Vaccine efficacy and safety

The replication-defective viral vector (adenovirus) vaccine of AstraZeneca/Oxford has exhibited an average efficacy of 70.4% [ 4 , 5 ], whereas that of the mRNA vaccine candidate developed by Pfizer/BioNTech (BNT162b2) was estimated at 95%, following the conclusion of phase III trial [ 6 ]. The latter team have already applied to US-FDA for emergency-use authorization [ 7 , 8 ]. Almost similar efficacy was also exhibited (94.1%) by mRNA-1273, the mRNA vaccine candidate developed by the US biotech company Moderna [ 9 , 10 ]. The efficacy of AstraZeneca/Oxford vaccine was evaluated in participants aged 18 years and older. The randomized controlled trial conducted across Brazil, UK, and South Africa, confirmed the safety and efficacy of AZD1222 against symptomatic COVID-19 [ 5 ]. The AstraZeneca/Oxford COVID-19 vaccine was found to possess similar immunogenicity across all age groups following the booster dose [ 2 ]. Similarly, the randomized controlled trial conducted to evaluate the efficacy of Pfizer/BioNTech vaccine (BNT162b2) enrolled 43,548 participants having 16 years of age or more [ 6 ]. The studies conducted among the younger and older adults have already established the immunogenicity and safety profile of the Pfizer/BioNTech vaccine [ 11 , 12 ]. The randomized controlled trial that confirmed the efficacy of Moderna vaccine (mRNA-1273) enrolled 30,420 participants aged 18 years and older [ 10 ]. Furthermore, the phase 2 trial that evaluated the safety and immunogenicity confirmed robust immune responses without any adverse effects in healthy adults vaccinated with the mRNA-1273 vaccine. The vaccine also exhibited similar immunogenicity in younger (18–55 years) and older (≥55 years) adults [ 13 ].

2. Storage and logistics

Although the average efficacy of AstraZeneca/Oxford COVID-19 vaccine candidate, AZD1222, is lower than those produced by Moderna and Pfizer/BioNTech, its recommended storage conditions are worth consideration ( Fig. 1 ) [ 4 , 8 , 14 ]. Pfizer/BioNTech requires temperature-controlled shippers for transporting vaccines at the recommended storage temperature of −70 °C ± 10 °C for up to 15 days. After thawing, the vaccine can only be stored at refrigerated conditions (2–8 °C) for up to 5 days [ 8 ]. The mRNA vaccine candidate of Moderna can remain stable at refrigerated conditions (2–8 °C) for 30 days; it can be stored for 6 months at −20 °C [ 14 ]. However, AZD1222 nCoV-19 can be transported, stored, and distributed at refrigerated conditions (2–8 °C) for a minimum of six months using existing healthcare settings [ 4 ]. Pfizer, the manufacturer of BNT162b2, has recently submitted data to the FDA that supports the use of their vaccine under more flexible conditions. The proposed alternative temperature requirements for the transportation and storage (−25 °C to −15 °C for up to 2 weeks) will allow the undiluted vials to be stored without the need for ultra-low cold storage equipments [ 15 ].

Comparison of COVID-19 vaccine candidates manufactured by AstraZeneca/Oxford, Moderna, and Pfizer/BioNTech. The figure is created using Biorender.com .

3. Cost of vaccine per dose

Since AstraZeneca/Oxford used a less expensive technology for the production of AZD1222, the total price per dose is less; it is the cheapest, at just 3–4 USD per dose, compared to the rest (Moderna, 32–37 USD and Pfizer/BioNTech, 19.50 USD) [ 16 ]. Fig. 1 illustrates the comparison of COVID-19 vaccine candidates manufactured by AstraZeneca/Oxford, Moderna, and Pfizer/BioNTech in terms of efficacy, storage requirements, and cost.

4. Vaccination in low- and middle-income countries

Following the reports of high efficacy, several countries, especially the wealthier ones, have already started pre-order/purchase of billions of COVID-19 vaccine doses triggering a “global vaccine race”. The UK government has already pre-ordered five million doses of mRNA-1273 vaccine from Moderna, this being its seventh deal with different pharmaceutical companies for securing early doses of the vaccine [ 9 ]. The total number of COVID-19 vaccine doses administered by different countries is illustrated in Fig. 2 (Updated on March 18, 2021). Among the countries, the USA occupies the top position with the administration of 118.31 million doses, followed by China (64.98 million), India (42.06 million), the US (28.27 million), and Brazil (13.34 million). However, in terms of the population that has received at least one dose, Israel tops the list with 59.6%, followed by UK (38.7%), Chile (29.1%), Bahrain (23.3%), and the USA (23.1%) [ 17 ]. Although India occupies the third position in terms of the total dose administered, it constitutes only about 2.5% of the total population [ 17 ].

Total number of COVID-19 vaccine dose administered as on March 18, 2021. Reproduced from Our World in Data ( https://ourworldindata.org/covid-vaccinations ) under CC BY license.

Several governments and research institutes have already invested both efforts and finances into developing vaccines that can protect their citizens from the virus. Although the process of vaccine development and evaluation seems to be rapid, very little is known about the logistics and implementation strategies required for vaccinating billions of people worldwide, especially in low- and middle-income countries. Success of a vaccine depends on the global vaccination coverage and its efficacy in inducing protective immunity. With limited access to advanced storage and logistic facilities, along with dearth of funds, attaining successful vaccine-induced heard immunity is obviously a challenge for low- and middle-income countries. COVAX is a global alliance initiated to provide such countries equitable access to effective and safe vaccines. However, they could only secure vaccines for 250 million people, much less than the actual requirement, thereby limiting the accessibility of poor countries to the vaccines [ 18 ]. COVAX intends to purchase two billion doses of COVID-19 vaccine by the end of 2021. This vaccine dose will only cover about 20% of the participating country's population. Therefore, the doses available with COVAX will be sufficient to vaccinate healthcare workers and the elderly [ 19 ].

Although Moderna and Pfizer have not announced the supply of vaccines to COVAX, AstraZeneca has already committed to providing vaccines to this cause [ 19 ]. The requirement of specific cold chain conditions for the storage and transport of vaccines manufactured by Moderna and Pfizer/BioNTech might prevent the low- and middle-income countries from using these vaccines through COVAX [ 19 ]. Achieving global vaccination coverage will be a challenge as it involves manufacturing billions of doses, coordinating storage, logistics, and equitable distribution of vaccines. Therefore, the low- and middle-income countries should focus on vaccinating the priority population (key workers/clinically vulnerable groups/elderly groups), since the available doses of vaccines will be insufficient to vaccinate the whole population.

5. Conclusion

The choice of vaccine for the immunization program depends on the availability, cost, efficacy, storage, and logistic requirements [ 20 , 21 ]. Despite their high efficacy, the recommended storage conditions of vaccines from Moderna and Pfizer/BioNTech make it difficult for the low- and middle-income countries to store, transport, and distribute them. On the contrary, AstraZeneca/Oxford offers an effective COVID-19 vaccine candidate for resource-constrained countries that is safe, immunogenic, cost-effective, and can be transported, stored, and distributed at refrigerated conditions. Furthermore, the governments have to establish policies on COVID-19 vaccination depending on their ability to procure vaccine doses. The low- and middle-income countries should focus on vaccinating the key workers/clinically vulnerable groups/elderly. This will enable them to protect the older adults who are at greater risk of death due to COVID-19. It is also recommended that the vaccination should be offered initially to the essential workers, especially frontline healthcare workers. Therefore, the low- and middle-income countries should attempt to use the available resources (vaccines) in the existing healthcare settings (storage and logistics) to the best.

Ethical approval

Not applicable.

Sources of funding

None to be stated.

Author contribution

All authors contributed equally - study concept or design, data collection, data analysis or interpretation, writing the paper.

Registration of Research Studies

Name of the registry: Not applicable.

Unique Identifying number or registration ID: Not applicable.

Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable.

Dr. Khan Sharun , Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly-243 122, Uttar Pradesh, India. Email: [email protected].

Dr. Kuldeep Dhama , Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly-243 122, Uttar Pradesh, India. Email: [email protected].

Provenance and peer review

Not Commissioned, internally reviewed.

Declaration of competing interest

Acknowledgments.

All the authors acknowledge and thank their respective Institutes and Universities.

Study at Cambridge

About the university, research at cambridge.

• For Cambridge students
• For our researchers
• Business and enterprise
• Colleges and Departments
• Email and phone search
• Give to Cambridge
• Museums and collections
• Events and open days
• Fees and finance
• Postgraduate courses
• How to apply
• Fees and funding
• Postgraduate events
• International students
• Continuing education
• Executive and professional education
• Courses in education
• How the University and Colleges work
• Visiting the University
• Annual reports
• Equality and diversity
• A global university
• Public engagement

Astrazeneca and Cambridge announce new joint PhD and clinical research scholarships

AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research. Two of the schemes are co-funded by the NIHR Cambridge Biomedical Research Centre, a partnership between Cambridge University Hospitals and University of Cambridge.

The new PhD schemes further strengthen the partnership between AstraZeneca and the University, supporting the development of a cadre of Cambridge scientists who can continue to compete with the very best in the world Sir Leszek Borysiewicz

The programmes reflect the long term commitment of AstraZeneca to the science base in the UK and the shared dedication of the company and the NIHR Cambridge Biomedical Research Centre University of Cambridge/Cambridge BRC to developing the next generation of world-class scientists. The schemes are as follows:

• AstraZeneca will fund a minimum of nine scholarships annually, divided across the departments of chemistry, biochemistry and pharmacology, with each running for a four-year period. AstraZeneca will also have the possibility of enrolling up to two of its employees annually as PhD students in one or more of the departments.
• MedImmune, AstraZeneca’s global biologics research and development arm, together with the School of Clinical Medicine and the School of the Biological Sciences at the University of Cambridge have established a collaborative PhD programme  which will  focus on both clinical and translational research, supporting up to six scholarships annually, with students spending equal amounts of time at the University and MedImmune’s laboratories in Cambridge. The NIHR Cambridge Biomedical Research Centre Training Theme will also co-fund these posts.
• AstraZeneca and MedImmune will fund one PhD scholarship and two academic clinical lectureships annually for four years under the University’s new Experimental Medicine Initiative. Each post will run for up to four years with the opportunity for placements within AstraZeneca or MedImmune. The NIHR Cambridge Biomedical Research Centre is also committed to the Experimental Medicine Initiative and will provide part funding for the Academic Clinical Lecturer and PhD posts.

All three schemes will start in the autumn. Students will be appointed by the University of Cambridge and will be supported by an academic supervisor from the University and an industrial supervisor from AstraZeneca or MedImmune to ensure that basic scientific research is closely aligned with real-world challenges of drug discovery and development. Joint Steering Committees comprising senior representatives from the University, AstraZeneca and MedImmune will oversee the schemes. Mene Pangalos, Executive Vice President, Innovative Medicines and Early Development at AstraZeneca, said: “For the UK to remain at the cutting edge of life science, it’s essential that we continue to invest in developing the next generation of scientists who can combine outstanding basic research with an understanding of its translation into new medicines for patients. These new scholarships are a great way to train young translational scientists and reinforce the shared commitment of AstraZeneca and the University of Cambridge to create an open, collaborative research environment where investigators can work side by side to push the boundaries of science.” Professor Sir Leszek Borysiewicz, Vice-Chancellor at the University of Cambridge, said:  “The new PhD schemes further strengthen the partnership between AstraZeneca and the University, supporting the development of a cadre of Cambridge scientists who can continue to compete with the very best in the world. Under the new schemes, Cambridge students will have a unique opportunity to develop their scientific knowledge across academia and industry.” Adapted from a press release from AstraZeneca

Read this next

Baby born deaf can hear after breakthrough gene therapy

UK's only research institute dedicated to understanding early cancer receives £11 million donation

Researchers redesign future mRNA therapeutics to prevent potentially harmful immune responses

New vaccine technology could protect from future viruses and variants

Credit: Sir Cam

Search news

Sign up to receive our newsletter.

The University's news digest summarises news from and about the University of Cambridge. Enter your email address, confirm you are happy to receive our emails and then select 'Subscribe'.

I wish to receive the University's news digest by email.

The University of Cambridge will use your email address to send you our University news digest email up to three times per week. We are committed to protecting your personal information and being transparent about what information we hold. Please read our email privacy notice for details.

• Philanthropy
• Future therapeutics
• Leszek Borysiewicz
• School of Clinical Medicine
• School of the Biological Sciences
• School of the Physical Sciences
• Department of Chemistry
• Department of Biochemistry
• Department of Pharmacology
• Office for Translational Research

Related organisations

• AstraZeneca

Connect with us

© 2024 University of Cambridge

• Contact the University
• Accessibility statement
• Freedom of information
• Privacy policy and cookies
• Statement on Modern Slavery
• Terms and conditions
• University A-Z
• Undergraduate
• Postgraduate
• Cambridge University Press & Assessment
• Research news
• About research at Cambridge
• Spotlight on...

Be a part of Open Innovation

Apply for one of our many programmes and collaborate with us

We invite you to explore our preclinical, clinical or other offerings to identify either a programme or a compound of interest and submit a brief, non-confidential concept proposal to us for review.

We accept submissions all year around for our preclinical and clinical research programmes. Additionally, we open more targeted challenges every six months to find new collaborators who can rapidly bring in real innovations and solutions to real challenges faced by our teams. 

View programmes

Master's Thesis Research

Prereq: All course work toward the degree must be completed. Note: Registration for this course is not available via telephone (UK-VIP) or webUK. For enrollment information contact the Graduate School at 257- 9390.

Half-time to full-time work on thesis. May be repeated to a maximum of six semesters.

• About AstraZeneca

Life at AstraZeneca

• Our Locations
• Information Technology
• BioPharmaceuticals
• BioPharmaceuticals R&D
• International
• Enabling functions
• Oncology R&D
• Early Talent

Inclusion & Diversity

• Application Hints & Tips

Keyword Search

City, State, or ZIP

SAP Master Data Specialist

Join us as an SAP Master Data Specialist in Cell Therapy, where you will play a pivotal role in ensuring complete and accurate data is maintained in SAP for all clinical and commercial products manufactured at the Rockville Manufacturing Center (RMC). This is your chance to make a significant impact on patients' lives by contributing to our innovative medicines delivery.

What you will do:

Responsible for creating and maintaining Bills of Materials (BOMs), Master Data, Recipes, and Resources in SAP.

Collaborate with various departments to ensure all SAP data is complete and accurate, ensuring on-time execution and shipping of all production batches.

Serve as a Supply Chain Organization (SCO) Core Team representative and Workstream Lead on technical projects.

Involve enabling the development and optimization of product structures as new products are introduced to the plant.

Work closely with Finance to perform initial cost rolls and define, implement, and maintain required controlling capability.

Your leadership will be crucial in optimizing and maximizing the utilization of SAP and other enterprise systems.

Minimum Qualifications:

Bachelor’s Degree preferred.

Minimum 5 years of in-depth supply chain experience and application of Enterprise Resource Planning specifically SAP (inventory and production planning functions), building, planning, and scheduling principles, master data, concepts, practices, and standards.

Experience with Lean Sigma or other operational excellence methodologies is strongly preferred.

Ability to proactively anticipate potential issues and conflicts and determine options for resolution. Escalates to functional management in a clear and concise manner

Must be organized, possess time management skills, can deal with ambiguity, and be able to manage changing priorities.

Must have strong interpersonal and communication skills to be able to provide timely feedback and communicate appropriately with other departments.

Preferred Qualifications:

Experience in a similar role within the pharmaceutical industry would be advantageous.

CPIM preferred.

At AstraZeneca, we are united behind one mission: finding the best solution to put our patients first. With constant new products and launches, there's never been a better time to join our Supply Chain team. We are driven by innovation and resilience, continuously seeking new and better ways to deliver medicines all the way to our patients. We foster a safe and positive space where ideas are welcomed, problem-solving is encouraged, and we work as a team to keep pushing the boundaries of Supply Chain. If you are driven, take smart risks, adapt quickly, and have a sharp focus on finding solutions, then AstraZeneca is the place for you.

Ready to make a bigger impact on patients? Apply now to join our team as an SAP Planning Architect!

Indirect leadership skills/partnering finance/manufacturing – be that leaders without direct reports.

AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.

We’ll keep you up-to-date

Sign up to be the first to receive job updates.

Email Address

Confirm Email

We are AstraZeneca, one of the world’s most forward-thinking and connected BioPharmaceutical companies. Explore our world.

At AstraZeneca, our purpose is to help patients all over the world by delivering life-changing medicines as one collaborative team.

The success of AstraZeneca is founded on innovation, creativity and diversity. Discover what this means for you.

Great culture, great work assignments, supportive management. Rotation opportunity within the company. They value inclusion and diversity.